Nanobiotix
Develops NBTXR3, hafnium oxide nanoparticles injected into tumors to boost radiotherapy, now licensed to Johnson & Johnson.
Nanobiotix, 24 Sept 2026Prices by TradingView, about 15 minutes delayed. Not investment advice.
- Ticker
- NBTX · Nasdaq
- Based in
- France
- Website
- nanobiotix.com ↗
- Filings
- SEC EDGAR ↗
How nano is it?
Pure play: nano is the business.
From the company's own filings or announcements, quoted word for word.
Describes itself as a clinical-stage nanomedicine company; its lead product is made of nanoparticles.
“NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a clinical-stage nanomedicine company”Nanobiotix via BioSpace, 4 Apr 2019
What we track
Its technologies, and how far each has got
From lab to listing
Company history
- DealCompany-reported
Licensed NBTXR3 to Janssen, a Johnson & Johnson company, for development and sale worldwide.
Nanobiotix, 24 Sept 2026
On the record
Latest steps
The newest dated events on the technologies above.
- Human trialCompany-reported
NBTXR3
Nanobiotix reported that the FDA had cleared changes to the Johnson & Johnson-led phase 3 trial in head and neck cancer, NANORAY-312, so that its final analysis can come sooner.
Nanobiotix, 24 Sept 2026 - Funding or dealCompany-reported
NBTXR3
Nanobiotix licensed NBTXR3 to Janssen, a Johnson & Johnson company, for development and sale worldwide.
Nanobiotix, 24 Sept 2026 - ApprovalCompany-reported
NBTXR3
Nanobiotix said its product, sold under the name Hensify, won a CE mark in Europe for locally advanced soft tissue sarcoma.
Nanobiotix via BioSpace, 4 Apr 2019
Not investment advice. We describe what companies do and what their own filings say; we never say whether to buy or sell.